title: A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells.
abstract: PAI-1 and PAI-2 (plasminogen-activator inibitor types 1 and 2) are inhibitors of cell surface uPA (urokinase plasminogen activator). However, tumour expression of PAI-1 and PAI-2 correlates with poor compared with good patient prognosis in breast cancer respectively. This biological divergence may be related to additional functional roles of PAI-1. For example, the inhibition of uPA by PAI-1 reveals a cryptic high-affinity site within the PAI-1 moiety for the VLDLr (very-low-density-lipoprotein receptor), which sustains cell signalling events initiated by binding of uPA to its receptor. These interactions and subsequent signalling events promote proliferation of breast cancer cells. Biochemical and structural analyses show that, unlike PAI-1, the PAI-2 moiety of uPA-PAI-2 does not contain a high-affinity-binding site for VLDLr, although uPA-PAI-2 is still efficiently endocytosed via this receptor in breast cancer cells. Furthermore, global protein tyrosine phosphorylation events were not sustained by uPA-PAI-2 and cell proliferation was not affected. We thus propose a structurally based mechanism for these differences between PAI-1 and PAI-2 and suggest that PAI-2 is able to inhibit and clear uPA activity without initiating mitogenic signalling events through VLDLr.
authors: School of Biological Sciences, University of Wollongong, NSW 2522, Australia.
authors: David R
authors: DR
authors: Croucher
authors: Darren N
authors: DN
authors: Saunders
authors: Gillian E
authors: GE
authors: Stillfried
authors: Marie
authors: M
authors: Ranson
mesh_terms: D001943:Breast Neoplasms / Q000737:chemistry / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D017395:Plasminogen Activator Inhibitor 1 / Q000737:chemistry* / Q000378:metabolism / Q000502:physiology*; D017396:Plasminogen Activator Inhibitor 2 / Q000737:chemistry* / Q000378:metabolism / Q000502:physiology*; D011485:Protein Binding / Q000502:physiology; D017433:Protein Structure, Secondary / Q000502:physiology; D017434:Protein Structure, Tertiary / Q000502:physiology; D011956:Receptors, Cell Surface / Q000378:metabolism; D011973:Receptors, LDL / Q000378:metabolism; D055293:Receptors, Urokinase Plasminogen Activator; D015398:Signal Transduction / Q000502:physiology*; D014407:Tumor Cells, Cultured; D014568:Urokinase-Type Plasminogen Activator / Q000737:chemistry / Q000378:metabolism
chemical_list: C524898:PLAUR protein, human; D017395:Plasminogen Activator Inhibitor 1; D017396:Plasminogen Activator Inhibitor 2; D011956:Receptors, Cell Surface; D011973:Receptors, LDL; D055293:Receptors, Urokinase Plasminogen Activator; C036053:VLDL receptor; D014568:Urokinase-Type Plasminogen Activator
references: Br J Cancer. 1998 May;77(10):1586-97
references: 9635833
references: Nat Med. 1998 Aug;4(8):923-8
references: 9701244
references: Thromb Haemost. 1998 Nov;80(5):822-8
references: 9843178
references: J Biol Chem. 1999 Mar 12;274(11):7412-20
references: 10066806
references: APMIS. 1999 Jan;107(1):120-7
references: 10190288
references: J Cell Biol. 1999 Jul 12;146(1):149-64
references: 10402467
references: Annu Rev Nutr. 1999;19:141-72
references: 10448520
references: J Cell Sci. 1999 Oct;112 ( Pt 19):3269-81
references: 10504332
references: Oncol Rep. 2005 Jul;14(1):105-12
references: 15944776
references: Thromb Haemost. 1999 Aug;82(2):298-304
references: 10605717
references: Cancer Res. 2000 Feb 1;60(3):636-43
references: 10676647
references: J Cell Biol. 2001 Feb 19;152(4):741-52
references: 11266465
references: J Biol Chem. 2001 Sep 7;276(36):33293-6
references: 11435447
references: J Clin Invest. 2001 Sep;108(6):779-84
references: 11560943
references: J Biol Chem. 2001 Nov 16;276(46):43374-82
references: 11546761
references: Nat Rev Cancer. 2005 Aug;5(8):591-602
references: 16056258
references: J Biol Chem. 2006 Apr 14;281(15):10206-13
references: 16459332
references: Mol Cell. 2006 Apr 21;22(2):277-83
references: 16630895
references: J Mol Biol. 2006 Sep 29;362(4):700-16
references: 16938309
references: FEBS J. 2006 Nov;273(22):5143-59
references: 17042782
references: Trends Endocrinol Metab. 2002 Mar;13(2):66-74
references: 11854021
references: Biol Chem. 2002 Jan;383(1):5-19
references: 11928822
references: Cancer Cell. 2002 Jun;1(5):445-57
references: 12124174
references: Biol Chem. 2003 Aug;384(8):1119-31
references: 12974381
references: Curr Pharm Des. 2004;10(1):39-49
references: 14754404
references: J Biol Chem. 2004 May 21;279(21):22595-604
references: 15001579
references: Exp Cell Res. 2004 Jul 1;297(1):259-71
references: 15194441
references: Clin Biochem. 2004 Jul;37(7):541-8
references: 15234235
references: Biochemistry. 1989 Nov 14;28(23):8951-66
references: 2690952
references: J Biol Chem. 1990 Jun 15;265(17):9904-8
references: 2161846
references: Cell. 1992 Oct 30;71(3):411-21
references: 1423604
references: J Biol Chem. 1993 Oct 15;268(29):21862-7
references: 7691818
references: J Biol Chem. 1994 Oct 14;269(41):25668-76
references: 7929271
references: Int J Cancer. 1995 Feb 8;60(4):501-6
references: 7829264
references: J Biol Chem. 1995 Sep 1;270(35):20855-61
references: 7657671
references: Nat Struct Biol. 1995 Oct;2(10):891-7
references: 7552714
references: J Biol Chem. 1995 Nov 3;270(44):26550-7
references: 7592875
references: Blood. 1995 Dec 1;86(11):4007-24
references: 7492756
references: Nature. 1996 Oct 3;383(6599):441-3
references: 8837777
references: Eur J Biochem. 1997 Sep 1;248(2):270-81
references: 9346278
references: Biochem J. 1998 Jan 1;329 ( Pt 1):55-63
references: 9405275
references: J Biol Chem. 1998 Mar 13;273(11):6358-66
references: 9497365
references: J Lipid Res. 2005 Aug;46(8):1721-31
references: 15863833